Cellectis S.A. (CLLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CLLS POWR Grades
- CLLS scores best on the Growth dimension, with a Growth rank ahead of 93.59% of US stocks.
- The strongest trend for CLLS is in Momentum, which has been heading up over the past 179 days.
- CLLS's current lowest rank is in the Momentum metric (where it is better than 4.72% of US stocks).
CLLS Stock Summary
- Of note is the ratio of CELLECTIS SA's sales and general administrative expense to its total operating expenses; merely 5.84% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of -18.96%, CELLECTIS SA's debt growth rate surpasses only 15.43% of about US stocks.
- As for revenue growth, note that CLLS's revenue has grown -61.65% over the past 12 months; that beats the revenue growth of only 3.24% of US companies in our set.
- Stocks that are quantitatively similar to CLLS, based on their financial statements, market capitalization, and price volatility, are HGEN, ARAV, CKPT, UTSI, and RVMD.
- Visit CLLS's SEC page to see the company's official filings. To visit the company's web site, go to www.cellectis.com.
CLLS Valuation Summary
- In comparison to the median Healthcare stock, CLLS's EV/EBIT ratio is 113.74% lower, now standing at -0.9.
- Over the past 97 months, CLLS's price/earnings ratio has gone down 55996.6.
Below are key valuation metrics over time for CLLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLLS | 2023-03-17 | 3.3 | 0.7 | -0.8 | -0.9 |
| CLLS | 2023-03-16 | 3.3 | 0.7 | -0.8 | -0.9 |
| CLLS | 2023-03-15 | 3.2 | 0.7 | -0.8 | -0.9 |
| CLLS | 2023-03-14 | 3.5 | 0.8 | -0.9 | -0.9 |
| CLLS | 2023-03-13 | 3.4 | 0.8 | -0.8 | -0.7 |
| CLLS | 2023-03-10 | 3.5 | 0.8 | -0.9 | -0.7 |
CLLS Growth Metrics
- The 2 year price growth rate now stands at -78.89%.
- The 3 year net cashflow from operations growth rate now stands at -42.08%.
- The 4 year net cashflow from operations growth rate now stands at -52.34%.
The table below shows CLLS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 22.181 | -107.306 | -104.321 |
| 2022-06-30 | 31.087 | -111.689 | -113.267 |
| 2022-06-30 | 31.087 | -111.689 | -113.267 |
| 2022-03-31 | 42.937 | -100.245 | -134.239 |
| 2021-12-31 | 67.071 | -104.562 | -114.197 |
| 2021-09-30 | 69.317 | -117.368 | -128.669 |
CLLS Stock Price Chart Interactive Chart >
CLLS Price/Volume Stats
| Current price | $2.04 | 52-week high | $5.04 |
| Prev. close | $1.96 | 52-week low | $1.77 |
| Day low | $1.96 | Volume | 23,300 |
| Day high | $2.11 | Avg. volume | 141,898 |
| 50-day MA | $2.53 | Dividend yield | N/A |
| 200-day MA | $2.64 | Market Cap | 113.39M |
Cellectis S.A. (CLLS) Company Bio
Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.
Latest CLLS News From Around the Web
Below are the latest news stories about CELLECTIS SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.
Monthly information on share capital and company voting rights(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights02/28/202355,583,76861,651,088 About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunothe |
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual MeetingNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research (AACR) Annual Meeting, to |
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsEntered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 product candidate fully manufactured in-house Encouraging preliminary results from Phase 1 AMELI-01 study |
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate UpdateNEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended D |
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market. The announcement will be followed by a conference call and live audio webcast on Thursda |
CLLS Price Returns
| 1-mo | -9.93% |
| 3-mo | 2.51% |
| 6-mo | -16.39% |
| 1-year | -56.03% |
| 3-year | -74.21% |
| 5-year | -93.57% |
| YTD | -2.86% |
| 2022 | -74.14% |
| 2021 | -69.99% |
| 2020 | 58.06% |
| 2019 | 2.82% |
| 2018 | -42.88% |
Continue Researching CLLS
Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...